Sichuan Kelun Pharmaceutical

Sichuan Kelun Pharmaceutical is a leading Chinese pharmaceutical conglomerate and a global leader in the production of intravenous (IV) solutions and large-volume injections. The company has successfully transitioned from a traditional manufacturing focus to a high-growth innovative model through its subsidiary, Kelun-Biotech, which specializes in oncology and antibody-drug conjugates (ADCs). Kelun maintains a vertically integrated business structure encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosages. The group gained significant international prominence through a multi-billion dollar strategic collaboration with Merck & Co. (MSD) to develop several ADC candidates, positioning it as a key player in the global biopharmaceutical innovation landscape.